- Coordinator
- Universita Degli Studi Di Padova, Italy
- Runs
- 1 November 2022 to 30 April 2027
- Status
- Running
- EU funding
- €1.4m
- Total cost
- —
- Partners
- 16 organisations in 11 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101086184
What the project is doing
In the project's own words, from its summary on CORDIS.
The long-term goal of MX-MAP is to develop a functional pipeline for the immune characterization of new 2D nanomaterials of MXene family, for the qualitative and quantitative assessment of the human immune compatibility and immune activity towards biomedical applications. The immune characterization of the tested materials on the basis of intrinsic physical-chemical and immunological properties, through the combination of the most innovative technologies such as single-cell mass cytometry (CyTOF), will open breakthrough perspectives for the development of new therapeutic approaches applying nanomaterials as immunomodulators, scaffolds for tissue engineering, cancer therapy, and antibacterial agents.
MX-MAP will develop key chemistry and immune-based strategies for MXene medical applications. The implication of this project extends beyond the specific nanoscience program greatly advancing the engineering process of 2D materials and their use in biomedicine. The MX-MAP project involves fourteen key players in European and non-European countries, including the United States, Canada, Saudi Arabia, and three partners from Ukraine, coming from academia and SMEs.
This program will provide strong support for the development of the careers of young brilliant scientists who want to grow towards an interdisciplinary vision of Science. Chemistry, biology, immunology, engineering, and cancer research are the expertise of MX-MAP. The senior team members are among the most influential scientists, including Prof. Yury Gogotsi (H-index=168) - inventor of MXenes, Prof. Klaus Ley (H-index=147) - one of the most cited immunologists worldwide, and Prof.
Husam N Alshareef (H-index=99). The Consortium is perfectly balanced in terms of equal gender presence; the project Coordinator Lucia Gemma Delogu is a female, and 2 out 4 of four WP leaders are female. The project embraces a large view of inclusiveness and diversity, including countries with smaller economies such as Ukraine.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Degli Studi Di Padova | Padova | Italy | Coordinator |
| Khalifa University of Science and Technology | Abu Dhabi | AE | Associatedpartner |
| The University of Manitoba | Manitoba | Canada | Associatedpartner |
| Universitaetsklinikum Essen | Essen | Germany | Participant |
| The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | Dublin | Ireland | Participant |
| Cambridge Raman Imaging SRL | Verona | Italy | Participant |
| Universita Degli Studi Di Sassari | Sassari | Italy | Participant |
| Latvijas Universitate | Riga | Latvia | Participant |
| Univerzitet U Novom Sadu | Novi Sad | Serbia | Participant |
| King Abdullah University of Science and Technology | Thuwal | SA | Associatedpartner |
| Ankara Universitesi | Tandogan Ankara | Türkiye | Participant |
| Materials Research Center | Kiev | Ukraine | Participant |
| Sumy State University | Sumy | Ukraine | Participant |
| Augusta University Research Institute, Inc. | Augusta | United States | Associatedpartner |
| Drexel University | Philadelphia | United States | Associatedpartner |
| La Jolla Institute for Allergy and Immunology | La Jolla Ca | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI